Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Phenylbutyrate in Pediatric SMA Type I
NCT00439218Phase 2Terminated
- Sponsor
- Westat
- Start
- Jan 2008
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sodium phenylbutyrate in spinal muscular atrophy type 1 (SMA1), sponsored by Westat. Started Jan 2008; status: terminated.
02
Drugs
sodium phenylbutyrate
03
Conditions
spinal muscular atrophy type 1 (SMA1)
Beyond the preview
Go deeper on NCT00439218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00439218.